德国银屑病关节炎患者使用生物制剂改善病情抗风湿药的医疗资源利用与相关医疗费用
基于德国InGef理赔数据库的回顾性分析纳入348例成年生物制剂初治银屑病关节炎患者,比较启用bDMARD前后12个月的医疗资源利用与费用。持续用药组总费用显著高于非持续组(€27,869±8,001 vs €21,897±10,600,P<0.001),但持续用药降低了住院、门诊、其他药物及病假成本。
要点
- 持续使用bDMARD组总费用显著高于非持续组,主要因bDMARD采购成本更高。
- 持续用药可部分抵消住院、门诊、其他药物及病假成本。
- 无论是否持续用药,启用bDMARD均增加总医疗费用。
核心结论
- 启用bDMARD无论是否持续均增加总医疗费用,但持续用药患者中观察到部分成本抵消。
研究设计与样本
- 回顾性分析德国InGef研究数据库2014年1月1日至2017年12月31日间确诊银屑病关节炎且有bDMARD理赔记录的成年生物制剂初治患者,索引日前365天无bDMARD处方。
主要发现
- 在10,954例银屑病关节炎诊断患者中,348例符合条件。
- 持续组索引后平均费用显著高于非持续组(€27,869±8,001 vs €21,897±10,600,P<0.001)。
- 持续组bDMARD采购成本显著更高(€23,996±4,818 vs €16,427±9,033,P<0.001)。
- 持续用药降低住院费用(-€760)、门诊费用(-€192)、其他药物费用(-€724)和病假费用(-€601)。
关键数值与推荐
- 非持续定义为治疗间隙或换用索引治疗以外的bDMARD。
- 主要结局为索引前12个月和索引后12个月总体及个体bDMARD的医疗资源利用和相关年医疗费用。
临床怎么用
- 临床决策中可考虑bDMARD持续用药对非药物医疗成本的潜在抵消作用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate health care costs associated with biologic disease-modifying antirheumatic drugs (bDMARDs) in a German real-world cohort of adult biologics-naive patients with psoriatic arthritis (PsA). METHODS: Claims data from the Institute for Applied Health Research Berlin (InGef) research database for patients with a PsA diagnosis and bDMARD claims record (index date) between January 1, 2014, and December 31, 2017, and no bDMARD prescriptions for 365 days before the index date were retrospectively analyzed. Primary outcomes were determination of health care resource utilization and associated annual health care costs for overall and individual bDMARDs in the 12-month pre-index and post-index periods. These outcomes were compared between persistent and nonpersistent groups. Nonpersistence was defined as treatment gap or switch to a bDMARD other than the index therapy. RESULTS: Among 10,954 patients with a PsA diagnosis, 348 were eligible. Although mean ± SD post-index costs were significantly higher in the persistent group than the nonpersistent group (€27,869 ± 8,001 versus €21,897 ± 10,600, P < 0 .001) due to higher bDMARD acquisition costs (€23,996 ± 4,818 versus €16,427 ± 9,033, P < 0.001), persistence reduced inpatient treatment costs (-€760), outpatient treatment costs (-€192), other drug costs (-€724), and sick leave costs (-€601). CONCLUSION: Although initiation of bDMARDs increased the total health care costs irrespective of persistence status, partial cost offsets were observed in the persistent patient population.
引用
- Sewerin P, Borchert K, Meise D, et al. Health Resource Utilization and Associated Health Care Costs of Biologic Disease-Modifying Antirheumatic Drugs in German Patients With Psoriatic Arthritis. Arthritis Care Res (Hoboken). 2022. PMID: 33742791. doi:10.1002/acr.24598
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。